Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
Bayer
University of California, Irvine
Eastern Cooperative Oncology Group
ViroMissile, Inc.
Dana-Farber Cancer Institute
Kaiser Permanente
University of Florida
Essen Biotech
MacroGenics
Avacta Life Sciences Ltd
Institut Curie
City of Hope Medical Center
M.D. Anderson Cancer Center
Ocellaris Pharma, Inc.
University of Southern California
Eli Lilly and Company
Var2 Pharmaceuticals
University of Illinois at Chicago
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Tanabe Pharma America, Inc.
Transgene
Bayer
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Hadassah Medical Organization
British Columbia Cancer Agency
Valo Therapeutics Oy
Institut Bergonié
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Washington University School of Medicine
University of California, Irvine
Instituto do Cancer do Estado de São Paulo
German Cancer Research Center
University Health Network, Toronto
Elevation Oncology
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Cybrexa Therapeutics